2-(3-Chloro-4-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98%, 100mg

3-FLUORO-4-PIPERIDONE HCL, 95.0%, 1g

1-((3AR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione, 98.0%, 100g

Recipiente de reacción con brida plana cilíndrico, graduado (2) Fondo plano, DN 150, 250 mm, Altura, 630 mm, 1 Pieza

2,6-Dibromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 95.0%, 250mg

(3-Bromo-5-isobutoxyphenyl)boronic acid, 95.0%, 100g

N,N-Dimethyl-2-phenoxyethanamine, 95.0%, 1g

6-Bromo-4-methylindoline-2,3-dione, 95%, 1g

1-(4-BROMOPHENYL)CYCLOBUTANOL, 95.0%, 5g

1-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)-3,3-dimethylindolin-2-one hydrochloride, 98%, 100mg

Tetrahydro-furan-3-carboxylic acid, 97.0%, 100g

6-Aminobenzo[d]thiazol-2(3H)-one, 95.0%, 25g

5'-(4-Carboxy-3-methylphenyl)-3,3''-dimethyl-[1,1':3',1''-terphenyl]-4,4''-dicarboxylic acid, 98%, 1g